Skip to main content
Adam Cohen, MD, Oncology, Philadelphia, PA

AdamDCohenMD

Oncology • Philadelphia, PA

Hematologic Oncology

Associate Professor, Medicine, Perelman School of Medicine, University of Pennsylvania. Director, Myeloma Immunotherapy, and Co-Director, Amyloidosis Program, Abramson Cancer Center, University of Pennsylvania

Join to view full profile

Dr. Cohen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Cohen's full profile

Already have an account?

  • Office

    3400 Civic Center Blvd
    # 2
    Philadelphia, PA 19104
    Phone+1 215-615-5858

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 1999

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2000 - 2024
  • NY State Medical License
    NY State Medical License 2001 - 2008
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
    Adam D. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to El...
    Adam D. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
    Adam D. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Immunotherapy in Myeloma 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • BCMA-Targeted Immunotherapy Can Lead to Durable Responses in Multiple Myeloma
    BCMA-Targeted Immunotherapy Can Lead to Durable Responses in Multiple MyelomaJanuary 20th, 2020
  • Cases Demonstrated Feasibility of Serial BCMA-Targeted Therapies in Myeloma
    Cases Demonstrated Feasibility of Serial BCMA-Targeted Therapies in MyelomaSeptember 10th, 2019

Grant Support

  • Targeting GITR For Tumor ImmunotherapyNational Cancer Institute2007–2008

Professional Memberships

Dr. Adam Cohen, Dr. Adam Cohen, MD, Dr. A Cohen, Dr. Adam D Cohen